Fedratinib
- Generic Name
- Fedratinib
- Brand Names
- Inrebic
- Drug Type
- Small Molecule
- Chemical Formula
- C27H36N6O3S
- CAS Number
- 936091-26-8
- Unique Ingredient Identifier
- 6L1XP550I6
- Background
Fedratinib, also known as SAR302503 and TG101348, is a tyrosine kinase inhibitor used to treat intermediate-2 and high risk primary and secondary myelofibrosis. It is an anilinopyrimidine derivative.
Fedratinib was granted FDA approval on August 16, 2019.
- Indication
Fedratinib is indicated for the treatment of adult patients with intermediate-2 or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis.
- Associated Conditions
- Secondary Myelofibrosis, Primary Myelofibrosis (PMF)
- Associated Therapies
- -
No news found
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath